Cradle
Cradle69
About
What does Cradle do?
Cradle Bio B.V. is a Dutch-Swiss biotechnology company that develops software using machine learning for protein engineering. Their platform accelerates the discovery and development of proteins by enabling faster engineering processes, reducing experimental rounds, and optimizing multiple objectives simultaneously. They serve industries such as pharmaceuticals, chemicals, food, and agriculture.
What is Cradle's revenue?
StartupHub estimates Cradle's annual revenue at $21.6M (range $11.2M to $43.9M, 67% confidence), based on comparable companies in the sector.
What is Cradle's valuation?
StartupHub estimates Cradle's effective valuation at $421.6M (range $256.0M to $614.4M, 16% confidence), based on comparable companies in the sector.
How much funding has Cradle raised?
Cradle has raised a total of $102M in funding. The most recent round on record is Series B.
Where is Cradle headquartered?
Cradle is headquartered in Amsterdam, Netherlands.
When was Cradle founded?
Cradle was founded in 2021.
What industry does Cradle operate in?
Cradle operates in Biotech, HealthTech, AI-Driven Protein Design, Drug Discovery, Generative AI, Machine Learning.
How many employees does Cradle have?
Cradle has approximately 112 people on record.
Cradle and Recursion both leverage AI and machine learning for drug discovery and protein engineering, aiming to accelerate the development of new therapeutics.
While Twist Bioscience focuses on synthetic DNA, Cradle's protein engineering platform could be seen as a complementary or alternative approach for companies seeking to design and optimize biological molecules for various applications.
Novartis, a global pharmaceutical company, would benefit from Cradle's AI-driven protein engineering platform to accelerate its drug discovery and development pipelines, particularly for biologics and novel therapeutics.
Amgen, a leading biotechnology company with a strong focus on developing innovative human therapeutics, could utilize Cradle's platform to optimize antibodies and other protein-based drugs, reducing experimental rounds and improving propert
DuPont, with its diverse portfolio in industrial biosciences, could leverage Cradle's technology to engineer enzymes and other bio-based materials for applications in food, agriculture, and chemicals, enhancing product performance and devel
Johnson & Johnson, a global healthcare giant, is already a customer, utilizing Cradle's platform to accelerate research and development of protein-based products.
Novonesis, a biosolutions company, is a customer that partners with Cradle to embed advanced AI into their innovation process, aiming to shorten development time for biosolutions.
Lundbeck, a pharmaceutical company specializing in brain diseases, is a customer that partners with Cradle for AI-driven brain disorder treatment discovery and optimization.
Buyer fit inferred by StartupHub from what Cradle sells and public signals about each company. Only rows badged "already a customer" are confirmed relationships.
Bayer, a global life science company, would gain a significant advantage in its therapeutic antibody pipeline by fully integrating Cradle's AI software platform, enhancing lead generation and optimization.
Thermo Fisher Scientific, a leader in scientific instrumentation and services, could fold Cradle's AI protein engineering software into its offerings to provide a more comprehensive solution for drug discovery and development workflows.
Precedent: Acquired PPD, 2021
Danaher, a diversified science and technology innovator, could integrate Cradle's platform to bolster its biotechnology and life sciences tools portfolio, offering advanced AI capabilities for protein design to its customers.
Precedent: Acquired Aldevron, 2021
Roche, a multinational healthcare company with a strong focus on pharmaceuticals and diagnostics, could acquire Cradle to enhance its internal protein engineering capabilities and accelerate the development of novel biologics.
Precedent: Acquired Spark Therapeutics, 2019
Strategic fit inferred by StartupHub from each buyer's own acquisition history. No deal, approach or discussion is implied.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Leading AI agency in Guwahati specializing in biological intelligence, generative AI, and regulatory systems for Asia's underrepresented populations.
Spearmint Resources Inc. is a Canadian mineral exploration company focused on lithium, gold, and antimony projects.
Eccoscience is a startup focused on developing AI-powered solutions for scientific research and discovery.
Feef is a voice-native AI agent that designs personalized fitness, nutrition, supplement, and recovery protocols, integrating them directly into your calendar.
Longevity and metabolic health platform offering personalized insights and interventions.
AI-powered platform for personalized health and longevity.
An entrant is a company tagged Biotech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 2 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.